Pressmeddelande -
New ETVAX® data will be presented during Vaccines Against Shigella and ETEC (VASE) conference in Mexico
The 2nd International Vaccines Against Shigella and ETEC(VASE) Conference will be held on June 12 to 14, in Mexico City, Mexico. Scientists, public health professionals, immunization leaders, vaccine industry representatives, international donors, and other experts around the globe will gather to share research and ideas toward making Shigella and enterotoxigenic Escherichia coli (ETEC) vaccines a reality. The aim of this collaborative, interactive gathering is to accelerate the development and introduction of vaccine, which are critical components of the global strategy to prevent and control diarrheal diseases.
Our ETEC-vaccine, ETVAX®, is of course on the agenda when the global development of ETEC vaccines will be discussed. ETVAX® is seen as the most advanced ETEC candidate in clinical development which in several clinical trials has showed impressive results, been proven safe and shown a much better ability to activate the immune system than expected.
Professor Ann-Mari Svennerholm from the University of Gothenburg and Dr Firdausi Qadri of icddr,b in Dhaka will present data from our Phase I/II study in Bangladesh. 450 study subjects were enrolled in this study where ETVAX® was tested for safety and immunogenicity in different age groups down to 6 months young infants. The successful ongoing phase IIb study in Finnish travellers going to Benin will be presented during a poster session.
Scandinavian Biopharma will be the sponsor of the Welcome Reception on June 12 at the Hyatt Regency in Mexico City. Scandinavian Biopharma will be represented by Björn Sjöstrand (CEO) and Nils Carlin (VP Research and Development). Sweden's ambassador in Mexico, Annika Thunborg, will attend the opening of the meeting.
Link to the meeting:
http://www.cvent.com/events/2nd-international-vase-conference/event-summary-40d943a666804e2d8c9bed83b6fba759.aspx
Ämnen
Scandinavian Biopharma
Scandinavian Biopharma is a Swedish research-based biotechnology company. The company is together with the American non-profit health organization PATH and researchers at the University of Gothenburg developing a drinkable diarrhea vaccine that protects against ETEC. The company's vision is that the vaccine will save hundreds of thousands of lives in the develoing countries, prevent antibiotic resistance and save the holiday for millions of travelers. Today, there is no ETEC vaccine available to meet these needs. A proof that we are on the right track and that our vaccine project is world-leading is that we are supported by PATH, an important partner of Bill and Melinda Gates Foundation for the development of new vaccines in the field of diarrhea diseases in developing countries. Scandinavian Biopharma also operates as distributor of specialty pharmaceuticals in the Nordic market.
